Comparison of Anti-oncotic Effect of TRPM4 Blocking Antibody in Neuron, Astrocyte and Vascular Endothelial Cell Under Hypoxia
Authors:
Open Access
- 19 October 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 8, 562584
Abstract
In stroke and other neurological diseases, Transient Receptor Potential Melastatin 4 (TRPM4) has been reported to cause oncotic cell death which is due to an excessive influx of sodium ions. Following stroke, hypoxia condition activates TRPM4 channel, and the sodium influx via TRPM4 is further enhanced by an increased TRPM4 expression. However, the effect of TRPM4 inhibition on oncotic cell death, particularly during the acute stage, remains largely unknown. Recently, we have developed a polyclonal antibody M4P that specifically inhibits TRPM4 channel. M4P blocks the channel via binding to a region close to the channel pore from extracellular space. Using M4P, we evaluated the acute effect of blocking TRPM4 in neurons, astrocytes, and vascular endothelial cells. In a rat stroke model, M4P co-localized with neuronal marker NeuN and endothelial marker vWF, whereas few GFAP positive astrocytes were stained by M4P in the ipsilateral hemisphere. When ATP was acutely depleted in cultured cortical neurons and microvascular endothelial cells, cell swelling was induced. Application of M4P significantly blocked TRPM4 current and attenuated oncosis. TUNEL assay, PI staining and western blot on cleaved Caspase-3 revealed that M4P could ameliorate apoptosis after 24 h hypoxia exposure. In contrast, acute ATP depletion in cultured astrocytes failed to demonstrate an increase of cell volume, and application of M4P or control IgG had no effect on cell volume change. When TRPM4 was overexpressed in astrocytes, acute ATP depletion successfully induced oncosis which could be suppressed by M4P treatment. Our results demonstrate that comparing to astrocytes, neurons, and vascular endothelial cells are more vulnerable to hypoxic injury. During the acute stage of stroke, blocking TRPM4 channel could protect neurons and vascular endothelial cells from oncotic cell death.Keywords
This publication has 41 references indexed in Scilit:
- Therapeutic Antibodies in StrokeTranslational Stroke Research, 2013
- The Sulfonylurea Receptor 1 (Sur1)-Transient Receptor Potential Melastatin 4 (Trpm4) ChannelJournal of Biological Chemistry, 2013
- Transient receptor potential melastatin 4 and cell deathPflügers Archiv - European Journal of Physiology, 2012
- On Potential Interactions between Non-selective Cation Channel TRPM4 and Sulfonylurea Receptor SUR1Journal of Biological Chemistry, 2012
- Novel Treatment Targets for Cerebral EdemaNeurotherapeutics, 2012
- Molecular mechanisms of microvascular failure in central nervous system injury—synergistic roles of NKCC1 and SUR1/TRPM4Journal of Neurosurgery, 2010
- Zinc-induced Neurotoxicity Mediated by Transient Receptor Potential Melastatin 7 ChannelsJournal of Biological Chemistry, 2010
- Intracellular calcium activates TRPM2 and its alternative spliced isoformsProceedings of the National Academy of Sciences, 2009
- De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injuryNature Medicine, 2009
- Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic strokeNature Medicine, 2006